Compare SACH & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | ACET |
|---|---|---|
| Founded | 2010 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 93.5M |
| IPO Year | 2017 | N/A |
| Metric | SACH | ACET |
|---|---|---|
| Price | $1.21 | $0.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $2.00 | ★ $8.50 |
| AVG Volume (30 Days) | 202.8K | ★ 2.1M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 16.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,906,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.80 | $0.45 |
| 52 Week High | $1.42 | $1.11 |
| Indicator | SACH | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 34.29 |
| Support Level | $1.00 | $0.50 |
| Resistance Level | $1.21 | $0.59 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 88.64 | 5.64 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.